Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 4 2000
Play
Audio Below:
At
this point in time we are set up to look at a comparison of venlafaxine
or another SSRI versus medroxyprogesterone acetate, three shots
versus another dose arm of the MPA to help sort out which is preferred
by crossover, effectiveness and all. And then the other thing we
are doing is looking at a number of the other newer antidepressants
to try to better sort out which of them are most efficacious and
what are the toxicity profiles associated with them. And hopefully,
along the line we can also sort out some mechanism by what they
are working: is it serotonin, is it epineprhine, is it dopamine,
or is it something else. We have, on the books, plans in concept
stage to compare several of the newer antidepressants in another
randomized comparison of these drugs.
Biopsy
confirmed benign breast disease, postmenopausal use of exogenous
female hormones, and breast carcinoma risk. Byrne,
C.; Connolly, J. L.; Colditz, G. A., and Schnitt, S. J.. Cancer.
89(10):2046-2052, 2000 Nov 15.
Postmenopausal
estrogens - Opposed, unopposed, or none of the above Willett, W. C.; Colditz, G., and Stampfer, M. (Reprint available
from: Willett WC Harvard Univ, Sch Publ Hlth, Dept Nutr 667 Huntington
Ave Boston, MA 02115 USA).. Jama: Journal of the American Medical
Association. 283(4):534-535, 2000 Jan 26. No abstract
Re:
Effect of hormone replacement therapy on breast cancer risk: Estrogen
versus estrogen plus progestin Archer, D. F.; Bush, T., and Nachtigall, L. E. (Reprint available
from: Nachtigall LE NYU, Sch Med, Dept Obstet & Gynecol 251
E 33rd St New York, NY 10016 USA).. Journal of the National Cancer
Institute. 92(23):1950-1951, 2000 Dec 6. No abstract
Estrogen
deficiency: In search of symptom control and sexuality. Loprinzi, C. L. and Barton, D. Journal of the National Cancer
Institute. 92(13):1028-1029, 2000 Jul 5. No abstract
